Development and preclinical assessment of a first-in-class small molecule inhibitor of FLIP

被引：0
|
作者：
Majkut, Joanna
Higgins, Catherine
Fox, Jennifer
Fiedler, Greti E.
Harrison, Timothy
Longley, Daniel B.
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
基金：
英国惠康基金;
关键词：
D O I：
10.1158/1538-7445.AM2017-LB-305
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-305
引用
收藏
页数：2
相关论文
共 50 条
  • [21] First-in-class small molecule inhibitors of ICOS/ICOSL interaction as a novel class of immunomodulators
    Abdel-Rahman, Somaya A.
    Swiderek, Katarzyna
    Gabr, Moustafa T.
    RSC MEDICINAL CHEMISTRY, 2023, 14 (09): : 1767 - 1777
  • [22] First-in-class Small-molecule Inhibitor of Nox4 Promotes Reversal of Established Pulmonary Fibrosis
    Hecker, L.
    Kato, K.
    Papageorgiou, J.
    Gokhale, V.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [23] Correction to: The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma
    C. Festuccia
    A. Mancini
    A. Colapietro
    G. L. Gravina
    F. Vitale
    F. Marampon
    S. Delle Monache
    S. Pompili
    L. Cristiano
    A. Vetuschi
    V. Tombolini
    Y. Chen
    T. Mehrling
    Journal of Hematology & Oncology, 11
  • [24] An oral first-in-class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer
    Ushijima, Miho
    Shiota, Masaki
    Matsumoto, Takashi
    Kashiwagi, Eiji
    Inokuchi, Junichi
    Eto, Masatoshi
    CANCER SCIENCE, 2022, 113 (05) : 1731 - 1738
  • [25] Feasibility and safety of targeting mitochondria for cancer therapy - preclinical characterization of gamitrinib, a first-in-class, mitochondriaL-targeted small molecule Hsp90 inhibitor
    Hayat, Umar
    Elliott, Gary T.
    Olszanski, Anthony J.
    Altieri, Dario C.
    CANCER BIOLOGY & THERAPY, 2022, 23 (01) : 117 - 126
  • [26] AN ORAL FIRST-IN-CLASS SMALL MOLECULE RSK INHIBITOR SUPPRESSES AR VARIANTS AND TUMOR GROWTH IN PROSTATE CANCER
    Shiota, Masaki
    Ushijima, Miho
    Matsumoto, Takashi
    Kashiwagi, Eiji
    Inokuchi, Junichi
    Eto, Masatoshi
    JOURNAL OF UROLOGY, 2022, 207 (05): : E98 - E99
  • [27] First-in-class: RGS protein inhibitor
    Kimple, A. J.
    Siderovski, D. P.
    MOLECULAR INTERVENTIONS, 2007, 7 (01) : 9 - 9
  • [28] Preclinical development of a selective, potent small molecule ALK inhibitor
    Lovly, Christine M.
    de Stanchina, Elisa
    Liang, Chris
    Pao, William
    CANCER RESEARCH, 2010, 70
  • [29] The discovery and preclinical characterization of AMG 176: A first-in-class Mcl-1 inhibitor in clinical development for multiple myeloma
    Hughes, Paul E.
    CANCER RESEARCH, 2017, 77
  • [30] Preclinical Pharmacokinetics and Pharmacodynamics of Pinometostat (EPZ-5676), a First-in-Class, Small Molecule S-Adenosyl Methionine Competitive Inhibitor of DOT1L
    Waters, Nigel J.
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2017, 42 (06) : 891 - 901
12345